New Publication: Simulating Cardiac Fibrosis

InvivoSciences, Inc. is collaborating with Drs. Elson and Qian to establish a novel mathematical model to understand the development of cardiac fibrosis during heart failure. The model will be used to identify and validate new therapeutic targets to prevent, slow, or reverse cardiac fibrosis.

CEO meets industry leaders including Sir Richard Branson

Goldman Sachs 10,000 small business SUMMIT Industry leaders, experts, and policymakers will speak with CEO during the two-day interactive program.      

Selected for BPS18 Podium Presentation

Dr. Brian Carlson is presenting an abstract entitled, “Simulating Drug-induced Arrhythmia Sensitivity Using An Expression-based Theoretical Model of Human iPSC-derived Cardiomyocytes” at Cardiac, Smooth, and Skeletal Muscle Electrophysiology and Regulation Session in Esplanade Room 154 on Tuesday, Feb 20 12:45 PM.   Moscone Center San Francisco, CA

Granted Patent in the US and Canada

 Official Documents of Granted Patents

Invited to attend 10,000 Small Business Summit hosted by Goldman Sachs

February 13-14, 2018 IVS was invited to attend Goldman Sachs 10,000 Small Businesses Summit: The Big Power of Small Business, one of the largest ever gatherings of small business owners focused on charting a path to help small businesses grow and compete successfully. The summit will be held in Washington, D.C.

Join us at BPS18

Our collaborator, Dr. Brian Carlson, in University of Michigan, Ann Abor is presenting the following abstract at 62nd Annual Meeting of Biophysical Society in San Francisco, CA February 17-21, 2018 Simulating Drug-Induced Arrhythmia Sensitivity Using an Expression-based Theoretical Model of Human iPSC-derived Cardiomyocytes Xin Gao1, Yue Yin 2, Neil J. Daily 2, Tyler Engel 2, Li Pang 3, Brian…
Read more

CSO at Rare Disease Summit in Novato, CA

Invivosciences was invited to attend Rare Diseases Summit November 15-17, 2017

CSO at the Japanese Safety Pharmacology Society Lecture

Dr. Wakatsuki was invited to present at Kirishima Symposium in Tokyo kirishima_4th_poster_jp

Predicting cardiotoxicity with engineered 3D human cardiac tissue models

Contact details: Ayla Annac, CEO/President of lnvivoSciences Inc.  +1-608-628-8035. aannac@ Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardio­vascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and…
Read more